Host defence peptide (antimicrobial peptide)

Structure and mechanisms

Most host defence peptides are short (typically under 50 amino acids), cationic, and amphipathic, which helps them bind to and perturb microbial membranes. Classical mechanisms include membrane disruption, pore formation, or translocation into the cell to inhibit internal targets. Their preference for negatively charged bacterial membranes explains why they are generally more active against prokaryotic cells than against neutral mammalian membranes, a key distinction when considering therapeutic use.

Biological roles and distribution

These peptides act against a broad spectrum of organisms: Gram-positive and Gram-negative bacteria, fungi, enveloped viruses and some parasites. They can also affect slow-growing organisms such as mycobacteria, including clinically important species like Mycobacterium tuberculosis. In addition to direct killing, many host defence peptides have immunomodulatory effects: they recruit immune cells, promote wound healing, and can dampen excessive inflammation.

Medical potential and limitations

Interest in host defence peptides has grown as antibiotic resistance rises. These peptides can kill strains that are resistant to some conventional antibiotics and often act rapidly in a bactericidal manner rather than merely inhibiting growth. Because of their dual antimicrobial and immune‑modulating properties they are being investigated for topical applications, inhaled formulations, and as templates for synthetic analogues.

• Advantages: broad spectrum activity, rapid killing, modulation of host responses.
• Challenges: susceptibility to proteolytic degradation, potential toxicity to host cells at high doses, manufacturing cost and delivery hurdles.

History, examples and notable facts

Antimicrobial peptides were discovered in many organisms over decades of research; classical human examples include defensins and the cathelicidin LL-37, while amphibian skin peptides such as magainins inspired early therapeutic work. Certain peptides can also recognize and kill altered host cells in laboratory studies, including some transformed or cancerous cells. Researchers continue to design stabilized analogues and conjugates to improve potency, selectivity and pharmacokinetics for clinical use.

Further reading

For introductions and current perspectives consult specialist reviews and experimental literature via trusted sources. Basic resources explain their role in innate immunity, chemical diversity and ongoing drug development efforts; more applied materials address formulation and regulatory challenges for peptide-based therapeutics. See introductory summaries and databases for deeper exploration: definition, innate immunity, and targeted reviews on resistance and clinical translation at antibiotic resistance, antibiotic therapy, mycobacterial activity, M. tuberculosis and experimental reports involving tumour cell activity.